01:10

What does the future hold for dendrimer nanoparticles in solid tumors?

01:30

Phase I/II trial of dendrimer-enhanced SN38 in patients with advanced solid tumors

01:32

Enhancing delivery of chemotherapies with dendrimer nanoparticles

00:51

Managing treatment-induced peripheral neuropathy in Black patients with breast cancer

00:56

Treatment strategies for chemotherapy-induced peripheral neuropathy

01:20

Challenges in developing and implementing new therapies for head and neck cancers

01:52

Treatment deintensification and immunotherapy in HPV16+ oropharyngeal cancer

00:51

Overview of managing CNS metastases in pediatric Ewing sarcoma

00:49

Challenges in managing pediatric patients with stage MS neuroblastoma

02:12

Tuvusertib and niraparib in advanced unresectable solid tumors

01:47

Challenges in radioligand therapy for patients with mCRPC

00:56

Safety findings and future development of targeted alpha particle therapy in prostate cancer

02:20

Emerging approaches in targeting CLDN18.2 in gastric cancer

03:21

Racial inequities in breast cancer outcomes and tumor biology in RxPONDER

03:27

Trial updates in neoadjuvant adjuvant therapies for early-stage NSCLC

01:21

INTerpath-002: pembrolizumab with a neoantigen therapy in completely resected NSCLC

03:58

JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC

01:15

BIG BANG: binimetinib, encorafenib, and cetuximab in BRAF non-V600E mutated mCRC

01:51

Personalizing chemotherapy in PDAC with AI-assisted transcriptomic signatures

02:08

Pooled analysis of management of nausea and vomiting in patients treated with T-DXd

03:07

Young-PEARL: palbociclib plus exemestane and OFS in HR+/HER2- breast cancer

01:42

Effects of proton pump inhibitor use on GI toxicities in patients receiving ICIs

01:57

Infliximab versus vedolizumab in treating immune-mediated diarrhea and colitis

02:38

Insights from the UPTIDER program in metastatic breast cancer

02:55

Analysis of BRCA1/2 mutations and other alterations in the monarchE trial

01:13

Next steps and clinical application of AI in oncology research

04:15

Developing a machine learning-based mammogram for HR+/HER2- early breast cancer

00:51

The importance of multidisciplinary collaboration and PROs in oncology

00:45

Identifying and managing adverse events of fruiquintinib for CRC

03:06

Evaluating the role of fruiquintinib in patients with refractory mCRC

00:33

The future of enfortumab vedotin in triple-negative and HR+/HER2- breast cancer

00:55

An overview of current management strategies for early-stage rectal cancer

00:48

Therapeutic cancer vaccine combination therapies in pancreatic cancer

01:21

Long-term outcomes of neoadjuvant DCF in locally advanced ESCC

01:33

Assessing the link between TILs and pCR in the NSABP B-41 trial

00:35

The potential role of ARV-766, an oral PROTAC AR degrader, in mCRPC

01:07

Initial results from Phase I/II Study of ARV-766 in mCRPC

03:02

PROs from TROPION-Breast01: datopotamab deruxtecan in HR+/HER2- breast cancer

02:41

Highlights in skin cancer at ASCO 2024

01:27

Link between hormone receptor status and outcomes in young patients with breast cancer

01:33

Anti-Müllerian hormone as a predictor of chemotherapy response in HR+/HER2- breast cancer

01:26

RxPONDER: chemotherapy and endocrine therapy in HR+/HER2- breast cancer

02:25

EAZ171: taxane-induced peripheral neuropathy in black women with breast cancer

01:11

IOB-032/PN-E40: pembrolizumab with a IO102-IO103 in melanoma and SCCHN

01:19

KEYNOTE-585: mPR and tumor downstaging as surrogate endpoints in G/GEJ

02:26

Final OS findings of zolbetuximab and FOLFOX6 in the SPOTLIGHT trial

00:42

Phase II trial of cemiplimab and ISA101b vaccine in HPV16+ cervical cancer

01:25

EV-202: enfortumab vedotin in pretreated HR+/HER2- breast cancer and TNBC

01:14

ReNeu: mirdametinib in NF1-associated symptomatic inoperable plexiform neurofibroma

03:32

TARGET-HPV: HB-200, a HPV16-specific immunotherapy, in oropharyngeal cancer

01:51

Enhancing trial prescreening accuracy and timeliness with human-AI teams

01:09

Clinical significance of the ReNeu trial in NF1- associated plexiform neurofibroma

00:53

How can ctDNA be used to monitor outcomes in colorectal cancer?

01:57

The emerging role of ctDNA as a predicative marker in dMMR/MSI-H colorectal cancer

02:51

COMBI-AD: long-term follow-up of dabrafenib and trametinib in BRAF-mutated melanoma

00:42

Role of endocrine therapy in early-stage HR-positive breast cancer

01:12

Addressing suboptimal ovarian suppression in PREFER and GIM 23 studies

00:54

Nonsurgical ablation as an emerging therapeutic option in breast cancer

01:01

Exploring extended adjuvant chemotherapy for luminal cancers

00:46

Debating radiation therapy after pathological complete response in breast cancer